RxDoctor Payments Data

Jack Brown, MD

Family Medicine · Sand Springs, OKNPI 1982699096

Payments from drug & device makers

$1,086in general payments, 2019–2025

Across 49 payments — averaging $22.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Otsuka America Pharmaceutical, Inc.$411
  • Avanir Pharmaceuticals, Inc.$273
  • Sunovion Pharmaceuticals Inc.$227
  • Teva Pharmaceuticals USA, Inc.$73
  • Neurocrine Biosciences, Inc.$26
  • Urovant Sciences Inc$22
  • plus $54 from 4 others

What the payments were for

  • Food & beverage$1,01493%
  • Education$737%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,086 in reported general payments places this provider in the 65th percentile of 1,730 family medicine providers in Oklahoma.

See all family medicine providers in Oklahoma

Medicare billing

Part B allowed, 2024
$1,257,582
Medicare patients
1,635
Services billed
16,876

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban2,652$873,127
TrulicityDulaglutide839$794,393
GemtesaVibegron805$206,843
IngrezzaValbenazine Tosylate27$186,317
XareltoRivaroxaban456$151,872
JardianceEmpagliflozin423$137,099
Invega SustennaPaliperidone Palmitate34$110,410
Austedo XrDeutetrabenazine29$108,242
OzempicSemaglutide97$106,834
NuedextaDextromethorphan Hbr/Quinidine137$105,494
JanuviaSitagliptin Phosphate310$103,864
BiktarvyBictegrav/Emtricit/Tenofov Ala25$94,883
Trelegy ElliptaFluticasone/Umeclidin/Vilanter135$92,620
RexultiBrexpiprazole88$91,485
EntrestoSacubitril/Valsartan180$82,033

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity$11$794,393839 claims
Sumitomo Pharma America, Inc.Gemtesa$13$206,843805 claims
Neurocrine Biosciences, Inc.Ingrezza$26$186,31727 claims
Teva Pharmaceuticals USA, Inc.Austedo Xr, Austedo$73$176,49447 claims
Avanir Pharmaceuticals, Inc.Nuedexta$273$105,494137 claims
Otsuka America Pharmaceutical, Inc.Rexulti$411$91,48588 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,730 family medicine providers in Oklahoma.

Other family medicine in Sand Springs

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →